Suppr超能文献

血清外泌体中 miR-146a-5p 的水平可预测顺铂治疗非小细胞肺癌的疗效。

MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer.

机构信息

Department of Clinical Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

出版信息

Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2650-2658.

Abstract

OBJECTIVE

Lung cancer is the most common cause of death in cancer worldwide, and cisplatin plays an important role in its treatment. However, the response to chemotherapy is poorly attributable to drug resistance. Our present study aimed to investigate the relation of the exosomal miR-146a-5p level with the chemosensitivity of NSCLC to cisplatin and the molecular mechanism that miR-146a-5p mediated to effect on chemotherapy response.

PATIENTS AND METHODS

The exosomes were isolated by ExoQuick kit. The exosomal morphology and particle size distribution were evaluated by the transmission electron microscopy and nanoSight assay respectively. Cell proliferation was detected using the MTT assay. NSCLC cells were infected with mimics or inhibitor to overexpress or downregulate miR-146a level. Besides, Quantitative real-time PCR, Western blot analysis, and immunohistochemistry were applied to detect the relative miRNA and protein levels.

RESULTS

Advanced NSCLC patients with low serum exosomal miR-146a-5p levels had higher recurrence rates than those with high levels. A549/DDP cells and exosomes expressed higher miR-146a-5p than A549. In the process of cisplatin-induced drug resistance, the expression of miR-146a-5p decreased in either NSCLC cell lines or the exosomes gradually. What's more, the overexpression of miR-146a-5p could reverse the resistance of A549/DDP. And the possible mechanism of miR-146a-5p increasing chemosensitivity of NSCLC to cisplatin could be targeting Atg12 to inhibit autophagy.

CONCLUSIONS

Serum exosomal miR-146a-5p may be a new biomarker predicting the efficacy of cisplatin for NSCLC patients and real-time monitoring drug resistance.

摘要

目的

肺癌是全球癌症死亡的最常见原因,顺铂在其治疗中发挥着重要作用。然而,化疗的反应很差归因于耐药性。本研究旨在探讨外泌体 miR-146a-5p 水平与非小细胞肺癌对顺铂化疗敏感性的关系,以及 miR-146a-5p 介导的分子机制对化疗反应的影响。

患者和方法

采用 ExoQuick 试剂盒分离外泌体。通过透射电子显微镜和纳米粒子跟踪分析分别评估外泌体的形态和粒径分布。使用 MTT 法检测细胞增殖。用 mimics 或抑制剂感染 NSCLC 细胞以过表达或下调 miR-146a 水平。此外,应用定量实时 PCR、Western blot 分析和免疫组织化学检测相对 miRNA 和蛋白水平。

结果

血清外泌体 miR-146a-5p 水平较低的晚期 NSCLC 患者复发率高于高水平患者。A549/DDP 细胞和外泌体表达的 miR-146a-5p 高于 A549。在顺铂诱导耐药的过程中,miR-146a-5p 的表达在 NSCLC 细胞系或外泌体中逐渐降低。此外,miR-146a-5p 的过表达可以逆转 A549/DDP 的耐药性。miR-146a-5p 增加 NSCLC 对顺铂化疗敏感性的可能机制可能是靶向 Atg12 抑制自噬。

结论

血清外泌体 miR-146a-5p 可能是预测 NSCLC 患者顺铂疗效的新生物标志物,并可实时监测耐药性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验